R-埃替拉韦 | 1177256-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: R-埃替拉韦
• 英文名称: elvitegravir
• 英文别名: (R)-elvitegravir；(R)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid；6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2R)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid
• CAS: 1177256-05-1
• 化学式: C₂₃H₂₃ClFNO₅
• 分子量: 447.891
• InChiKey: JUZYLCPPVHEVSV-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,4-二甲氧基苯乙酮 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 溴 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 51.0h， 生成 R-埃替拉韦
  参考文献：
  名称：

  Elvitegravir的改进合成

  摘要：

  开发了一种新的HIV整合酶抑制剂elvitegravir（1）的活性药物成分的改进方法。它从市售的2,4-二甲氧基苯乙酮开始，将其选择性卤化至位置5。将5卤代苯乙酮与碳酸二烷基酯缩合，得到相应的苯甲酰乙酸酯。他们先用N，N-二甲基甲酰胺二甲基乙缩醛，再用（S）-缬氨醇处理，得到相应的中间体丙烯酸苯甲酰酯。通过用N，O处理可以实现芳香族亲核取代2-甲氧基，从而环化为所需的1,4-二氢喹啉-4-氧代衍生物。-双（三甲基甲硅烷基）-乙酰胺，它也作为三甲基甲硅烷基衍生物保护羟基。最后，Negishi与2-氟-3-氯苄基溴化锌的偶联以及随后的水解反应提供了elvitegravir（1）。首选的变体是从2,4-二甲氧基苯乙酮开始的七步法，可提供29.3％的依维韦韦。

  DOI：

  10.1002/jhet.2477

文献信息

• [EN] A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR<br/>[FR] NOUVEAU PROCÉDÉ DE PRODUCTION ET NOUVEAUX INTERMÉDIAIRES DE SYNTHÈSE D'ELVITEGRAVIR
  申请人：ZENTIVA KS

  公开号：WO2014056464A1

  公开（公告）日：2014-04-17

  The present solution relates to an improved production method of elvitegravir of formula I, which is being clinically evaluated for treatment of HIV infection. Elvitegravir of formula I is produced via the intermediate of formula II, the preparation of which is also an object of the present solution.

  本解决方案涉及一种改进的公式I的elvitegravir生产方法，该方法正在临床评估用于治疗HIV感染。公式I的elvitegravir是通过公式II的中间体生产的，该中间体的制备也是本解决方案的目标。
• [EN] AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR<br/>[FR] PROCÉDÉ DE PRODUCTION AMÉLIORÉ ET NOUVEAUX INTERMÉDIAIRES DE SYNTHÈSE D'ELVITÉGRAVIR
  申请人：ZENTIVA KS

  公开号：WO2014056465A1

  公开（公告）日：2014-04-17

  The present solution relates to an improved production method of elvitegravir of formula (I), which is being subjected to clinical trials for treatment of HIV infection. Elvitegravir of formula (I) is produced via the intermediate of formula (I)I, the preparation of which is also an aspect of the present solution.

  本解决方案涉及一种改进的艾滋病治疗临床试验中使用的公式（I）的依利格瑞制剂的生产方法。公式（I）的依利格瑞是通过公式（I）I的中间体制备而成的，其制备也是本解决方案的一个方面。
• STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND
  申请人：SATOH MOTOHIDE

  公开号：US20100204271A1

  公开（公告）日：2010-08-12

  Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2θ(°) as measured by X-ray powder diffractometry.

  提供稳定的晶体化合物A，其化学式为6-(3-氯-2-氟苯基)-1-[(S)-1-羟甲基-2-甲基丙基]-7-甲氧基-4-氧代-1,4-二氢喹啉-3-羧酸。该晶体呈现出特定的X射线粉末衍射图案，其特征衍射峰在衍射角度2θ(°)处，通过X射线粉末衍射测量得出。
• Antiviral prodrugs and nanoformulations thereof
  申请人：Board of Regents of the University of Nebraska

  公开号：US11166957B2

  公开（公告）日：2021-11-09

  The present invention provides prodrugs and methods of use thereof.

  本发明提供了原药及其使用方法。
• Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors
  作者：Motohide Sato、Hiroshi Kawakami、Takahisa Motomura、Hisateru Aramaki、Takashi Matsuda、Masaki Yamashita、Yoshiharu Ito、Yuji Matsuzaki、Kazunobu Yamataka、Satoru Ikeda、Hisashi Shinkai

  DOI：10.1021/jm900460z

  日期：2009.8.13

  Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto-enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited marked antiretroviral activity. Here, we show the synthesis and the detailed structure-activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)- 1-((2,S)-1-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-4-oxo- 1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and 6-(3-chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-4-dihydroquinoline-3-carboxylic acid 49, which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.